Lilly Singapore Centre for Drug Discovery (LSCDD) focuses on drug discovery in the areas of cancer and metabolic disorders - some of the world's most challenging disease conditions.

The role of epigenetics in these diseases is subject to intense research worldwide. At LSCDD we focus on developing drugs targeting epigenetics as a new approach to help treat cancer and diabetic patients.

Biomarker discovery and patient tailoring approaches are conducted at LSCDD to identify the right drug for the right patient, resulting in improved patient outcomes.

We believe that the best way to find the next generation of drugs is to use next generation technologies. As such the computational science tools and platforms developed at the Singapore facility are now used throughout Eli Lilly and Company worldwide to aid research.

Contributions, collaborations and support from like-minded companies and the wider scientific community can enhance and accelerate Lilly's ability to find 'Answers That Matter'. Thus, LSCDD is conducting many of its activities through a network of partners. We are constantly seeking mutually beneficial partnerships to enable our key areas of focus.